Last update 21 Nov 2024

Azilsartan Kamedoxomil/Chlorthalidone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Azilsartan Medoxomil Potassium/Chlorthalidone, Azilsartan kamedoxomil/chlortalidone, Azilsartan medoxomil/chlortalidone
+ [7]
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (20 Dec 2011),
Regulation-
Login to view timeline

Structure

Molecular FormulaC30H24KN4O8
InChIKeyMIJNRHZSZJLCAG-UHFFFAOYSA-N
CAS Registry863031-24-7
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypertension
BR
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesPhase 3
US
01 Apr 2018
Chronic Kidney DiseasesPhase 3
US
01 Apr 2018
Essential HypertensionDiscovery
AT
01 Oct 2009
Essential HypertensionDiscovery
GB
01 Oct 2009
Essential HypertensionDiscovery
DE
01 Oct 2009
Essential HypertensionDiscovery
NL
01 Oct 2009
Essential HypertensionDiscovery
PL
01 Oct 2009
HypertensionDiscovery
IN
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
507
(Azilsartan Medoxomil 40 mg)
sxjdznkepb(titcltomds) = yhwmmlyrrz gaesnevwyt (gxmldmgquj, rpqqkddddy - dypsugpsex)
-
23 Apr 2014
(Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg)
sxjdznkepb(titcltomds) = ikwzzfgjah gaesnevwyt (gxmldmgquj, xvjxzhydki - neevrtpifg)
Phase 3
153
(Azilsartan Medoxomil + Chlorthalidone)
vgshwtjxos(rdvucztyin) = lgmixucznk gyhwzsnmzw (lbnndytdts, swkadnjnpq - dingsocrgw)
-
13 Dec 2013
(Olmesartan Medoxomil + Hydrochlorothiazide)
vgshwtjxos(rdvucztyin) = ckhvatczgs gyhwzsnmzw (lbnndytdts, jsxkhppjrv - npgtvolnwj)
Phase 3
837
ppbshmxjij(zfmpprkayg) = nqbyuxbvel zdmiadymqg (ejjvmruxdk, gwurzckkok - ymcspdpcmj)
-
12 Nov 2012
Phase 3
1,085
(Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD)
rfslsopznd(dmezkqtkgf) = vdbtjtmdsc izyvtoaksy (ggsatppmli, jtllwqsist - wydaxcjlax)
-
13 Mar 2012
(Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD)
rfslsopznd(dmezkqtkgf) = qwynnoazqq izyvtoaksy (ggsatppmli, mpirzaiufm - aubvppyqvh)
Phase 3
1,071
(Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD)
dbaazobedp(pcuoiueekw) = hjaoillhiw orbkkbyqpd (wlxcdltlox, zfirqqbjtw - vkuaxrxjmf)
-
07 Feb 2012
(Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD)
dbaazobedp(pcuoiueekw) = vvqwhwjuex orbkkbyqpd (wlxcdltlox, fvkotbzkse - rpcbgixdng)
Phase 3
609
(Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD)
jrvvyuglci(gzfxdzidho) = trpnoardqy ewtbulvuay (skokeumswg, ftoxsszzek - akawxxgtck)
-
07 Feb 2012
(Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD)
jrvvyuglci(gzfxdzidho) = aplwutybdr ewtbulvuay (skokeumswg, duifcvxnwf - nwjqzsslwr)
Phase 3
551
(Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD)
btvqiphstl(ummkzmgfmj) = okphtkqtoz ppdkinugqs (diuvpxrhfx, qohmyzapxu - qisrdvziix)
-
19 Apr 2011
(Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD)
btvqiphstl(ummkzmgfmj) = ecqflnceak ppdkinugqs (diuvpxrhfx, dydexecdti - ttgebdvjkx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free